Understanding MPN-U: Your Diagnosis Explained

Receiving a diagnosis of Myeloproliferative Neoplasm, Unclassifiable (MPN-U) can feel confusing. You may feel that the term “unclassifiable” implies a lack of certainty or a failure to find an answer. In reality, MPN-U is a recognized, specific category of blood cancer used by major health organizations like the World Health Organization (WHO, using MPN-NOS) and the International Consensus Classification (ICC, using MPN-U) ^[1][2].

This diagnosis means your medical team has confirmed you have a myeloproliferative neoplasm (a group of diseases where the bone marrow makes too many blood cells), but your specific case does not perfectly fit the “textbook” definitions of more common subtypes like Polycythemia Vera (PV), Essential Thrombocythemia (ET), or Primary Myelofibrosis (PMF) ^[1][3].

What is an MPN?

To understand MPN-U, it helps to understand the basic mechanism of all myeloproliferative neoplasms (MPNs). Your bone marrow contains stem cells, which are the “factory workers” responsible for producing red blood cells, white blood cells, and platelets.

In an MPN, an acquired genetic change (mutation) occurs in one of these stem cells. This is generally an acquired change over your lifetime, not an inherited trait you passed on. This mutation acts like a broken “on” switch, telling the cell to grow and divide even when the body doesn’t need more blood cells ^[4].

• The Signaling Pathway: Most MPNs involve the JAK-STAT pathway, a communication line inside the cell. When this pathway is stuck “on,” it leads to the overproduction of blood cells ^[4].
• The Mutations: The most common mutation is JAK2 V617F, found in approximately 65% to 72% of MPN-U cases depending on the study population ^[5]. Other common mutations include CALR and MPL ^[5][6]. If none of these three major driver mutations are found, the disease is sometimes called “triple-negative”—meaning negative for these three drivers, not that no genetic abnormality exists ^[7].

What this diagnosis does and does not tell you

• What it does tell you: It confirms you have a true clonal myeloid neoplasm requiring specialized, long-term hematology care.
• What it does not tell you: The label alone does not determine your specific prognosis, whether you will require immediate treatment, or whether your disease will eventually evolve into a different MPN.

Why is it Called “Unclassifiable”?

The word “unclassifiable” is a technical term, not a sign of confusion. Doctors use it when your blood counts, bone marrow appearance, and genetic tests show clear signs of an MPN, but the features are mixed or at an early stage ^[1][8].

For example, a patient might have the high platelet counts seen in ET but the bone marrow patterns of early-stage Myelofibrosis ^[9]. Or, they may have a mutation that usually belongs to PV but blood counts that don’t reach the required thresholds for that diagnosis ^[10].

Key Reasons for an MPN-U Diagnosis:

1. Early Stage: The disease may be caught so early that it hasn’t developed the classic features of a specific subtype ^[2].
2. Overlapping Features: You may have characteristics of two different MPNs at the same time ^[5].
3. Atypical Findings: Your specific combination of mutations and blood counts might be rare and not fit current classification rules ^[1].

How Rare is MPN-U?

MPN-U is much less common than the “classical” MPNs. While exact numbers vary by study and classification era, research suggests that MPN-U accounts for approximately 5% of all MPN diagnoses under strict criteria ^[11].

To put this in perspective, population registries have found an incidence rate of roughly 0.8 cases per 100,000 people per year ^[12]. Because it is rare, it is often helpful to be seen by a specialist—a hematologist-oncologist—who focuses specifically on myeloproliferative neoplasms.

What to Expect

Because MPN-U is a “mixed” category, the experience of the disease varies significantly from person to person ^[13]. Some cases remain stable for many years (indolent), while others may be more active ^[13][12].

Over time, as the disease progresses or more data is gathered, your doctor may be able to reclassify your diagnosis into a more specific subtype ^[2]. Regular monitoring of your blood counts and physical exams to check for splenomegaly (an enlarged spleen) are standard parts of care ^[13].

You may also have the opportunity to participate in research. For example, the MPN PROGRESSion Registry is an observational study that tracks symptoms and treatments for people with various MPNs, including MPN-U, to help researchers better understand these rare conditions [NCT07362225]. Always discuss research participation with your clinician.